Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys

J. C. Morrill, C. J. Peters

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Rhesus macaques, intravenously inoculated with virulent Rift Valley fever virus, develop viremia and biochemical evidence of liver damage and serve as a model for human disease. Some of these monkeys suffer more serious disease with hemorrhagic phenomena and approximately 20% die with frank hemorrhage. Presently, the only Rift Valley fever vaccine approved for use in humans is a formalin-killed product that requires annual booster vaccinations. Efforts to produce an improved vaccine to replace the present vaccine have led to a mutagen-attenuated strain of Rift Valley fever virus that was found to be markedly attenuated for rhesus macaques and showed promise as a vaccine candidate for human use. Neurovirulence testing in rhesus monkeys showed that, while the vaccine was not completely innocuous, residual lesions were no more severe than the currently used 17D yellow fever vaccine.

Original languageEnglish (US)
Pages (from-to)2994-3002
Number of pages9
JournalVaccine
Volume21
Issue number21-22
DOIs
StatePublished - Jun 20 2003
Externally publishedYes

Fingerprint

Rift Valley Fever
Rift Valley fever
Mutagens
Macaca mulatta
Virulence
pathogenicity
Vaccines
vaccines
Rift Valley fever virus
Yellow Fever Vaccine
Yellow fever virus
Viremia
viremia
Formaldehyde
Haplorhini
human diseases
formalin
Vaccination
lesions (animal)
hemorrhage

Keywords

  • Neurovirulence
  • Rift Valley fever
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys. / Morrill, J. C.; Peters, C. J.

In: Vaccine, Vol. 21, No. 21-22, 20.06.2003, p. 2994-3002.

Research output: Contribution to journalArticle

Morrill, J. C. ; Peters, C. J. / Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys. In: Vaccine. 2003 ; Vol. 21, No. 21-22. pp. 2994-3002.
@article{03e72814e3604744958dfe0b2dda3ea9,
title = "Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys",
abstract = "Rhesus macaques, intravenously inoculated with virulent Rift Valley fever virus, develop viremia and biochemical evidence of liver damage and serve as a model for human disease. Some of these monkeys suffer more serious disease with hemorrhagic phenomena and approximately 20{\%} die with frank hemorrhage. Presently, the only Rift Valley fever vaccine approved for use in humans is a formalin-killed product that requires annual booster vaccinations. Efforts to produce an improved vaccine to replace the present vaccine have led to a mutagen-attenuated strain of Rift Valley fever virus that was found to be markedly attenuated for rhesus macaques and showed promise as a vaccine candidate for human use. Neurovirulence testing in rhesus monkeys showed that, while the vaccine was not completely innocuous, residual lesions were no more severe than the currently used 17D yellow fever vaccine.",
keywords = "Neurovirulence, Rift Valley fever, Vaccine",
author = "Morrill, {J. C.} and Peters, {C. J.}",
year = "2003",
month = "6",
day = "20",
doi = "10.1016/S0264-410X(03)00131-2",
language = "English (US)",
volume = "21",
pages = "2994--3002",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "21-22",

}

TY - JOUR

T1 - Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys

AU - Morrill, J. C.

AU - Peters, C. J.

PY - 2003/6/20

Y1 - 2003/6/20

N2 - Rhesus macaques, intravenously inoculated with virulent Rift Valley fever virus, develop viremia and biochemical evidence of liver damage and serve as a model for human disease. Some of these monkeys suffer more serious disease with hemorrhagic phenomena and approximately 20% die with frank hemorrhage. Presently, the only Rift Valley fever vaccine approved for use in humans is a formalin-killed product that requires annual booster vaccinations. Efforts to produce an improved vaccine to replace the present vaccine have led to a mutagen-attenuated strain of Rift Valley fever virus that was found to be markedly attenuated for rhesus macaques and showed promise as a vaccine candidate for human use. Neurovirulence testing in rhesus monkeys showed that, while the vaccine was not completely innocuous, residual lesions were no more severe than the currently used 17D yellow fever vaccine.

AB - Rhesus macaques, intravenously inoculated with virulent Rift Valley fever virus, develop viremia and biochemical evidence of liver damage and serve as a model for human disease. Some of these monkeys suffer more serious disease with hemorrhagic phenomena and approximately 20% die with frank hemorrhage. Presently, the only Rift Valley fever vaccine approved for use in humans is a formalin-killed product that requires annual booster vaccinations. Efforts to produce an improved vaccine to replace the present vaccine have led to a mutagen-attenuated strain of Rift Valley fever virus that was found to be markedly attenuated for rhesus macaques and showed promise as a vaccine candidate for human use. Neurovirulence testing in rhesus monkeys showed that, while the vaccine was not completely innocuous, residual lesions were no more severe than the currently used 17D yellow fever vaccine.

KW - Neurovirulence

KW - Rift Valley fever

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0038512604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038512604&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(03)00131-2

DO - 10.1016/S0264-410X(03)00131-2

M3 - Article

VL - 21

SP - 2994

EP - 3002

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 21-22

ER -